Food and Drug Administration granted approval Tuesday to
the first bird flu vaccine intended as a stopgap measure
until a better immunization is developed.
The vaccine, made by French company Sanofi-Aventis, will
not be sold commercially, but rather stockpiled by the government
if the virus H5N1 mutates into a form that is spread easily
from human to human.